Skip to Main Content

Paper Details

Pevonedistat with azacitidine in older patients with TP53-mutated AML: a phase 2 study with laboratory correlates.
Blood Adv
4
2023
Pevonedistat, TP53, TP53-mutated AML, azacitidine, patients
Author NameAffiliation
Scott H KaufmannMayo Clinic
Scott H KaufmannMayo Clinic
Scott H KaufmannMayo Clinic
Scott H KaufmannMayo Clinic
Scott H KaufmannMayo Clinic
Scott H KaufmannMayo Clinic
Prapti PatelUT Southwestern Medical Center
Michael W DeiningerUniversity of Utah Huntsman Cancer Institute
John T SchillerDavid Geffen School of Medicine at University of California los angeles
Tara L LinUniversity of Kansas Medical Center
Elie TraerKnight Cancer Institute, Oregon Health & Science University
Robert H CollinsUT Southwestern Medical Center
Uma BorateThe Ohio State University
Brian J DrukerKnight Cancer Institute, Oregon Health & Science University
  • 1 - 14

Datasets

Release 1.2